PTC Therapeutics | PTCT - Operating Expenses


PTC Therapeutics reported $226.66M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 270.12M 2.55M Jun/2026
Alnylam Pharmaceuticals USD 1.06B 160.97M Jun/2026
Amgen USD 11.69B 6.9B Jun/2026
BioCryst Pharmaceuticals USD -553.84M 700.01M Mar/2026
Biogen USD 2.98B 1.02B Jun/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Cytokinetics USD 200.58M 4.46M Mar/2026
Daiichi Sankyo JPY 489.64B 21.08B Jun/2026
Enanta Pharmaceuticals USD 126.59M 346.51M Dec/2025
Gilead Sciences USD 3.95B 19.57B Jun/2026
Incyte USD 973.64M 4.65B Jun/2026
Ionis Pharmaceuticals USD 370.24M 6.24M Jun/2026
Ironwood Pharmaceuticals USD 57.33M 8.63M Dec/2024
Karyopharm Therapeutics USD 61.83M 9.9M Mar/2026
Novartis USD 10.2B 912M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
PTC Therapeutics USD 226.66M 19.64M Mar/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Roche Holding CHF 18.9B 2.12B Jun/2026
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sarepta Therapeutics USD 372.37M 480.65M Mar/2026
TG Therapeutics USD 218.66M 48.54M Jun/2026
Ultragenyx Pharmaceutical USD 289M 16M Jun/2026
Vertex Pharmaceuticals USD 2.07B 217.1M Jun/2026
Xencor USD 82.38M 513K Mar/2026